{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=52&q=gene+therapy",
    "query": {
      "q": "gene therapy",
      "page": 52
    },
    "page_size": 10
  },
  "pagination": {
    "page": 52,
    "page_size": 10,
    "total_count": 5852,
    "total_pages": 586,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=53&q=gene+therapy&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=51&q=gene+therapy&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T12:00:02.089Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01064440",
      "title": "Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Critical Limb Ischemia"
      ],
      "interventions": [
        {
          "name": "Low Dose VM202",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High Dose VM202",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Helixmith Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 52,
      "start_date": "2010-07-09",
      "completion_date": "2023-11-17",
      "has_results": true,
      "last_update_posted_date": "2025-10-06",
      "last_synced_at": "2026-10-17T12:00:02.089Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Orange, California • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01064440"
    },
    {
      "nct_id": "NCT00062855",
      "title": "Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Skin Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Gene Modified Neuroblastoma Cells",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "GENETIC"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 9,
      "start_date": "1997-11",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2012-10-29",
      "last_synced_at": "2026-10-17T12:00:02.089Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00062855"
    },
    {
      "nct_id": "NCT04628585",
      "title": "Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Safety and efficacy assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Genetix Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "53 Years",
        "sex": "ALL",
        "summary": "2 Years to 53 Years"
      },
      "enrollment_count": 85,
      "start_date": "2020-10-21",
      "completion_date": "2038-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-20",
      "last_synced_at": "2026-10-17T12:00:02.089Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Oakland, California • Atlanta, Georgia + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04628585"
    },
    {
      "nct_id": "NCT05879926",
      "title": "Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ovarian Function Suppression + Aromatase Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Adjuvant Chemotherapy + Ovarian Function Suppression",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 3960,
      "start_date": "2023-10-18",
      "completion_date": "2034-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-17T12:00:02.089Z",
      "location_count": 1226,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05879926"
    },
    {
      "nct_id": "NCT06654050",
      "title": "Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma",
        "Malignant Mesothelioma (MM)",
        "Early-stage Mesothelioma",
        "Subclinical Mesothelioma",
        "BRCA1-Associated Protein-1 (BAP1) Mutations",
        "Early-stage BAP1-associated Malignancies"
      ],
      "interventions": [
        {
          "name": "alrizomadlin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 0,
      "start_date": "2026-03-16",
      "completion_date": "2026-03-16",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-10-17T12:00:02.089Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06654050"
    },
    {
      "nct_id": "NCT01898208",
      "title": "Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bacteremia",
        "Fungemia",
        "Bloodstream Infection"
      ],
      "interventions": [
        {
          "name": "FilmArray testing",
          "type": "DEVICE"
        },
        {
          "name": "Antimicrobial Stewardship",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Bacterial culture",
          "type": "OTHER"
        },
        {
          "name": "Susceptibility testing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "Up to 99 Years"
      },
      "enrollment_count": 743,
      "start_date": "2013-08",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2016-03-15",
      "last_synced_at": "2026-10-17T12:00:02.089Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01898208"
    },
    {
      "nct_id": "NCT04619589",
      "title": "Characterization of Dyschromic Hypertrophic Scar",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Burn Scar",
        "Hypertrophic Scar",
        "Hyperpigmentation",
        "Hypopigmented Scar"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Medstar Health Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2019-05-21",
      "completion_date": "2023-06-28",
      "has_results": false,
      "last_update_posted_date": "2023-11-03",
      "last_synced_at": "2026-10-17T12:00:02.089Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04619589"
    },
    {
      "nct_id": "NCT03275974",
      "title": "Glutamine PET Imaging Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "RAS Wild Type",
        "Stage IV Colorectal Cancer",
        "Stage IVA Colorectal Cancer",
        "Stage IVB Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Carbon C 11 Glutamine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluorine F 18 L-glutamate Derivative BAY94-9392",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood Draw",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-04-27",
      "completion_date": "2025-12-23",
      "has_results": false,
      "last_update_posted_date": "2026-01-02",
      "last_synced_at": "2026-10-17T12:00:02.089Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03275974"
    },
    {
      "nct_id": "NCT06005974",
      "title": "A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AXIN1 Gene Mutation",
        "APC Gene Mutation",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "REC-4881",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Recursion Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2024-01-15",
      "completion_date": "2025-02-24",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-10-17T12:00:02.089Z",
      "location_count": 13,
      "location_summary": "San Diego, California • Santa Barbara, California • Denver, Colorado + 10 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06005974"
    },
    {
      "nct_id": "NCT07867340",
      "title": "A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "C-Reactive Protein"
      ],
      "interventions": [
        {
          "name": "LY5625573",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 96,
      "start_date": "2026-09",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-17T12:00:02.089Z",
      "location_count": 2,
      "location_summary": "Los Alamitos, California • Dallas, Texas",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07867340"
    }
  ]
}